drugset / Trial / NCT02244203
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 60732 in Healthy Male Volunteers
RandomizedSingle-groupDouble-blindTreatment
Summary
Single Rising Dose (SRD) study: First evaluation of safety, tolerability, pharmacokinetics and pharmacodynamics of BI 60732
Timeline
- Start
- 2009-02
- Primary completion
- 2009-07
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BI 60732 | Unknown | 0.25 mg | — |
| Subject | BI 60732 | Unknown | 0.5 mg | — |
| Subject | BI 60732 | Unknown | 1 mg | — |
| Subject | BI 60732 | Unknown | 2 mg | — |
| Subject | BI 60732 | Unknown | 4 mg | — |
| Subject | BI 60732 | Unknown | 20 mg | — |
| Subject | BI 60732 | Unknown | 50 mg | — |
| Subject | BI 60732 | Unknown | 100 mg | — |
| Subject | BI 60732 | Unknown | 150 mg | — |
| Subject | BI 60732 | Unknown | 200 mg | — |
Indications
No indication recorded.